The story has been updated to include comments from a conference call this morning.

NEW YORK (GenomeWeb News) – GenMark Diagnostic's third-quarter revenues increased four-fold year over year, the Carlsbad, Calif.-based molecular diagnostics firm reported after the close of the market on Wednesday.

For the three months ended Sept. 30, revenues rose to $5.3 million from $1.3 million, with product revenues reaching $5.2 million, compared to $1.2 million a year ago. Licensing and other revenues fell to $62,000 from $110,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.